

Understanding the Medicare Drug Price Negotiation Program

The Inflation Reduction Act (IRA) provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition through the **Medicare Drug Price Negotiation Program (MDPNP)**. These negotiated prices, referred to as **Maximum Fair Prices (MFPs)**, are based on agreements reached between the Centers for Medicare and Medicaid Services (CMS) and participating drug manufacturers.

The year in which MFPs become effective for the drugs selected for that round is referred to as the **Initial Price Applicability Year (IPAY)**. Medicare Part D drugs are eligible beginning with the first round of drugs selected for IPAY 2026 and Medicare Part B drugs become eligible beginning with the third round for IPAY 2028.

This document provides an overview of the drugs selected for IPAY 2026, 2027, and 2028, and key dates to be aware of as the program develops.

Learn more

For additional resources and information on the program, scan or click the QR code to visit [CMS.gov](https://www.cms.gov).



Overview of selected drugs

IPAY 2026

First round of Medicare Part D drugs selected for MFPs effective January 1, 2026:

- Eliquis[®]
- Enbrel[®]
- Entresto[®]
- Farxiga[®]
- Fiasp[®]; Fiasp[®] FlexTouch; Fiasp[®] PenFill; NovoLog[®]; NovoLog[®] Flexpen; NovoLog[®] PenFill
- Imbruvica[®]
- Januvia[®]
- Jardiance[®]
- Stelara[®]
- Xarelto[®]

IPAY 2027

Second round of Medicare Part D drugs selected for MFPs effective January 1, 2027:

- Austedo[®]; Austedo XR[®]
- Breo Ellipta
- Calquence[®]
- Ibrance[®]
- Janumet[®]; Janumet[®] XR
- Linzess[®]
- Ofev[®]
- Otezla[®]
- Ozempic[®]; Rybelsus[®]; Wegovy[®]
- Pomalyst[®]
- Tradjenta[®]
- Trelegy Ellipta
- Vraylar[®]
- Xifaxan[®]

CMS fact sheet

Scan or click the QR code to view 2026 MFPs for the drugs listed above.



CMS fact sheet

Scan or click the QR code to view 2027 MFPs for the drugs listed above.



IPAY 2028

Third round of Medicare Part B and Part D drugs selected for MFPs effective January 1, 2028:

- Anoro Ellipta
- Biktarv[®]
- Botox[®]; Botox[®] Cosmetic
- Cimzia[®]
- Cosentyx[®]
- Entyvio[®]
- Erleada[®]
- Kisqali[®]
- Lenvima[®]
- Orencia[®]
- Rexulti[®]
- Trulicity[®]
- Verzenio[®]
- Xeljanz[®]; Xeljanz[®] XR
- Xolair[®]
- Tradjenta[®] has also been selected for renegotiation based on criteria required by the law

CMS fact sheet

The deadline for CMS to publish agreed-upon MFPs for the drugs listed above is November 30, 2026. Scan or click the QR code to learn more about the drugs selected for IPAY 2028.



Key milestones through 2028

- 2023**
 - August 29**

CMS announced 10 Medicare Part D drugs selected for the first round of negotiations
- 2024**
 - August 15**

CMS published MFPs for the first round of selected drugs for IPAY 2026
- 2025**
 - January 17**

CMS announced 15 Medicare Part D drugs selected for the second round of negotiations
 - November 30**

Deadline for CMS to publish the MFPs for second round of selected drugs for IPAY 2027
- 2026**
 - January 1**

MFPs are effective for the first round of drugs selected in 2023
 - January 27**

CMS announced 15 new Medicare Part B or Part D drugs selected for the third round of negotiations and one drug selected for renegotiation
 - April**

CMS will host patient-focused and clinical-focused engagement sessions to solicit public input
 - November 1**

The negotiation and renegotiation period between CMS and participating drug manufacturers ends
 - November 30**

Deadline for CMS to publish any agreed-upon MFPs for the third round of selected drugs for IPAY 2028
- 2027**
 - January 1**

MFPs are effective for the second round of drugs selected in 2025
 - March 1**

Deadline for CMS to publish explanations of agreed-upon MFPs for third round of selected drugs
- 2028**
 - January 1**

MFPs are effective for the third round of selected drugs selecting in 2026